VYNE Therapeutics (VYNE) Insider Trading & Ownership → 'If I Die, I’d Trust 50% of My Daughters’ Inheritance in ONE Stock.' (From Stansberry Research) (Ad) Free VYNE Stock Alerts $2.29 +0.01 (+0.44%) (As of 04:29 PM ET) Add Compare Share Share Insider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends VYNE Therapeutics (NASDAQ:VYNE) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage1.80%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$50,830.00Number OfInsiders Selling(Last 12 Months)0 Get VYNE Insider Trade Alerts Want to know when executives and insiders are buying or selling VYNE Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address VYNE Insider Buying and Selling by Quarter Ad The Oxford ClubAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years. See His Breakdown of the Seven Stocks You Should Own Here. VYNE Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/15/2023Patrick G LeporeDirectorBuy13,000$3.91$50,830.00 (Data available from 1/1/2013 forward) VYNE Insider Trading Activity - Frequently Asked Questions Who is on VYNE Therapeutics's Insider Roster? The list of insiders at VYNE Therapeutics includes Mutya Harsch, Patrick G Lepore, and Perceptive Advisors Llc. Learn more on insiders at VYNE. What percentage of VYNE Therapeutics stock is owned by insiders? 1.80% of VYNE Therapeutics stock is owned by insiders. Learn more on VYNE's insider holdings. Which VYNE Therapeutics insiders have been buying company stock? The following insiders have purchased VYNE shares in the last 24 months: Mutya Harsch ($25,000.00), and Patrick G Lepore ($100,430.00). How much insider buying is happening at VYNE Therapeutics? Insiders have purchased a total of 43,000 VYNE shares in the last 24 months for a total of $125,430.00 bought. More Insider Trading Tools from MarketBeat Related Companies: KZR Insider Trading MNOV Insider Trading HOOK Insider Trading CNTX Insider Trading CTMX Insider Trading CRVS Insider Trading GOSS Insider Trading AMLX Insider Trading OPTN Insider Trading KPTI Insider Trading Insider Tracking Tools: CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country: U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles: The Top 3 Stocks Sold by Insiders This QuarterTop 4 Stocks With Notable Insider Buying3 Small Cap Tech Stocks That Insiders Are Buying3 Stocks Insiders are Buying That Should be on Your RadarInsider Trading is Good News for These Stocks This page (NASDAQ:VYNE) was last updated on 6/11/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredNVDA to close the AI “wealth window’ June 25?On Tuesday, June 25, in front of executives from nearly every major tech company in existence, key leaders at ...Paradigm Direct | Sponsored"If I Die, I’d Trust 50% of My Daughters’ Inheritance in ONE Stock.""I'd Feel Secure Putting 50% of My Kids' Inheritance in THIS Stock" One Wall Street millionaire bought AAPL...Stansberry Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredMoonshot Coins for the Current Crypto RunDid you see bitcoin crossed $70k again? Don't miss the next bull run. Because while Bitcoin and Ethereum s...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding VYNE Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share VYNE Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.